GlassScriptPhysician profile
Benjamin B Johnson
NPI 1518339951
$11,213.27
in general payments reported to CMS, 2019-2025
34 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $932 · 2022: $1,548 · 2023: $4,930 · 2024: $1,536 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,046 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,452 · Travel and Lodging: $1,146 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,046.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,452.00 |
| Travel and Lodging | $1,145.98 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,508.70 | 2021-2025 | Linq II, Azure Xt Dr Mri Surescan, Reveal Linq |
| Aop Health US, LLC | $1,095.78 | 2025 | Rapiblyk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.09 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $609.18 | 2021-2025 | |
| Pfizer INC. | $398.20 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $319.44 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $315.29 | 2021-2024 | Xarelto |
| Amgen INC. | $271.81 | 2021-2025 | Repatha, Repatha |
| Abiomed | $246.78 | 2022-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $210.33 | 2023-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $209.22 | 2021-2025 | Verquvo |
| Werfen USA LLC | $121.94 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $111.70 | 2023-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $110.12 | 2021-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $103.22 | 2024 | Arcalyst |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $95.88 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $71.10 | 2021-2025 | Onpattro |
| Scpharmaceuticals INC. | $66.49 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $50.40 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $48.42 | 2022-2024 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.02 | 2021-2023 | Lifevest |
| Kestra Medical Technology Services, INC. | $38.32 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $34.57 | 2025 | Attruby |
| Astellas Pharma US INC | $22.95 | 2023 | Lexiscan |
| Vifor Pharma, INC. | $19.79 | 2021 | |
| Amarin Pharma, INC. | $18.00 | 2022 | |
| Esperion Therapeutics, INC. | $16.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.55 | 2021 | |
| Daiichi Sankyo INC. | $16.00 | 2024 | Injectafer |
| Chiesi USA, INC. | $15.69 | 2022 | |
| Mannkind Corporation | $15.32 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $14.48 | 2021 | |
| Edwards Lifesciences Corporation | $13.63 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $9.88 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.